HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BAO PHARMA-B

16.090

0.000

Volume:325.10K

Turnover:5.21M

Market Cap:5.21B

PE:-11.83

High:16.650

Open:16.650

Low:15.880

Close:16.090

52wk High:206.000

52wk Low:15.670

Shares:324.00M

HK Float Shares:153.00M

Volume Ratio:1.31

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.360

ROE:-30.55%

ROA:-10.79%

PB:2.81

PE(LYR):-11.83

PS:90.89

Loading ...

Overview Company News Filings

Shanghai Bao Pharmaceuticals announces annual shareholder meeting

Stock Track | BAO PHARMA-B Soars 6.67% Intraday on Chairman's Share Purchase Plan and Proposed Buyback Authorization

BAO PHARMA-B (02659) Chairman Dr. Liu Yanjun Plans to Increase Shareholding

Shanghai Bao Pharma says unaware of reasons behind unusual H-share moves

Stock Track | BAO PHARMA-B Plummets 64.33% Intraday as Annual Report Reveals Widening Losses

宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强

Bulletin Express

BAO PHARMA-B (02659): From Biotech to Foundational Operator in the 18A Sector

BAO PHARMA-B (02659) Gains Acceptance for Recombinant Ulinastatin (BJ044) IND Application, Pioneering New Era in Recombinant Protein Therapeutics

Subcutaneous Administration Breakthrough Arrives as KJ017 Gains Approval, BAO PHARMA-B (02659) Emerges as Hub for Large-Molecule Drugs

Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth

BAO PHARMA-B (02659) Addresses Biopharma Supply Chain Challenges with Technology-Driven Solutions

BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product

Shanghai Bao Secures China Approval for Innovative Subcutaneous Delivery Adjuvant

MT Newswires Live

Bao Pharma’s Human Hyaluronidase Injection Receives NMPA Marketing Approval

Bulletin Express

BAO PHARMA-B (02659) Receives NMPA Approval for Recombinant Human Hyaluronidase Injection

Shanghai Bao says NMPA approves human hyaluronidase injection for marketing

Shanghai Bao Pharmaceuticals - Nmpa Approves Human Hyaluronidase for Injection (Kj017) for Marketing

THOMSON REUTERS

Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance

Bulletin Express

BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected

BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02659/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"BAO PHARMA-B","latestPrice":16.09,"timestamp":1787299687043,"preClose":16.09,"halted":0,"volume":325100,"delay":0,"changeRate":0,"floatShares":153000000,"shares":324000000,"eps":-1.36,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:08:07","open":16.65,"high":16.65,"low":15.88,"amount":5214062,"amplitude":0.047856,"askPrice":16.21,"askSize":100,"bidPrice":16.09,"bidSize":12800,"shortable":0,"etf":0,"ttmEps":-1.35,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":16.09,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.313981310032103,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":153000000,"roa":"-10.79%","roe":"-30.55%","lyrEps":-1.36,"volumeRatio":1.313981310032103,"shares":324000000,"dividePrice":0,"high":16.65,"amplitude":0.047856,"preClose":16.09,"low":15.88,"week52Low":15.67,"pbRate":"2.81","psRate":"90.89","week52High":206,"institutionHeld":0,"latestPrice":16.09,"committee":0.984496,"eps":-1.36,"divideRate":0,"volume":325100,"delay":0,"ttmEps":-1.35,"open":16.65,"prevYearClose":77.55,"prevWeekClose":16.9,"prevMonthClose":17.25,"prevQuarterClose":18,"fiveDayClose":16.9,"twentyDayClose":17.25,"sixtyDayClose":25.68,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-08-21","current":-11.918519,"percent":1,"low":-150.791275,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"high":-11.379099,"avg":-48.460281,"sd":35.791886,"marketCap":5245041771},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-05","current":-15.389804,"twenty":-78.220574,"median":-65.202887,"eighty":-19.743808,"marketCap":7041199644},{"date":"2026-06-12","current":-13.774642,"twenty":-77.936107,"median":-64.592987,"eighty":-19.178821,"marketCap":6297961903},{"date":"2026-06-18","current":-12.785133,"twenty":-77.726882,"median":-64.454748,"eighty":-18.7468,"marketCap":5857886926},{"date":"2026-06-26","current":-11.736313,"twenty":-77.358698,"median":-62.675612,"eighty":-18.25553,"marketCap":5352615655},{"date":"2026-07-03","current":-13.348826,"twenty":-77.285436,"median":-61.290684,"eighty":-17.828553,"marketCap":6092593580},{"date":"2026-07-10","current":-14.187594,"twenty":-77.122448,"median":-60.663453,"eighty":-17.509903,"marketCap":6467472265},{"date":"2026-07-17","current":-12.348746,"twenty":-76.777398,"median":-59.36056,"eighty":-15.389804,"marketCap":5649258788},{"date":"2026-07-24","current":-12.28898,"twenty":-76.640212,"median":-57.965274,"eighty":-14.102609,"marketCap":5623180271},{"date":"2026-07-31","current":-12.265678,"twenty":-76.228711,"median":-57.553252,"eighty":-13.925373,"marketCap":5623180271},{"date":"2026-08-07","current":-12.759971,"twenty":-76.015489,"median":-56.434485,"eighty":-13.758151,"marketCap":5861146740},{"date":"2026-08-14","current":-11.978357,"twenty":-75.491436,"median":-55.967849,"eighty":-13.50755,"marketCap":5509086758},{"date":"2026-08-21","current":-11.379099,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"marketCap":5245041771}],"updateTime":1787454437619},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632953299","title":"Shanghai Bao Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953299","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953299?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:42","pubTimestamp":1777898534,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals schedules annual general meeting in Shanghai on May 26, 2026.Shareholders will vote on 2025 annual report, final accounts, 2026 budget, board and supervisors’ reports, profit distribution plan, director remuneration for 2026.Resolution seeks reappointment of Ernst & Young as 2026 auditor, with board authorized to set fees up to RMB 2.85 million .Meeting also set to elect executive, non-executive, independent non-executive directors for second board session.Special resolutions include mandates to issue shares, repurchase H shares, abolish board of supervisors, amend articles of association and related policies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLNxXd2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133074617","title":"Stock Track | BAO PHARMA-B Soars 6.67% Intraday on Chairman's Share Purchase Plan and Proposed Buyback Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=1133074617","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133074617?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:49","pubTimestamp":1777859346,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock price soared 6.67% during intraday trading on Monday, marking a significant rebound for the pharmaceutical company.The surge follows an announcement that Board Chairman and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174280952","title":"BAO PHARMA-B (02659) Chairman Dr. Liu Yanjun Plans to Increase Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=1174280952","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174280952?lang=en_us&edition=fundamental","pubTime":"2026-05-03 19:02","pubTimestamp":1777806140,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) announced that the company has received a notification from its Board Chairman and a member of the controlling shareholder group, Dr. Liu Yanjun. Based on his confidence in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604711","title":"Shanghai Bao Pharma says unaware of reasons behind unusual H-share moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604711","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632604711?lang=en_us&edition=fundamental","pubTime":"2026-05-03 18:25","pubTimestamp":1777803949,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals issued a clarification on unusual price and trading volume moves in its H shares, stating it was not aware of any reason for the moves, any undisclosed price-sensitive information, or any information needed to avoid a false market.Chairman Liu Yanjun notified board he intends to increase his shareholding via open-market purchases within three months, capped at 38,893,903 H shares to maintain minimum public float compliance.Controlling shareholder group held about 40.57% of issued shares as of announcement date; planned purchases not expected to trigger a mandatory offer under Hong Kong takeover rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nNDL7vKn7k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152362481","title":"Stock Track | BAO PHARMA-B Plummets 64.33% Intraday as Annual Report Reveals Widening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1152362481","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152362481?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:30","pubTimestamp":1777530603,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock plummeted 64.33% during intraday trading on Thursday, marking a severe decline for the biotechnology company.The sharp drop followed the release of the company's annual report,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107062675","title":"宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强","url":"https://stock-news.laohu8.com/highlight/detail?id=1107062675","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107062675?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289425,"startTime":"0","endTime":"0","summary":"上海宝医药股份有限公司（「宝医药-B」或「公司」；股份代号：02659）于2025年在香港联合交易所有限公司主板挂牌上市，并于本年度全面推进合成生物学与重组生物药研发制造。公司年报显示，核心产品的临床进展稳步推进，全年收入大幅提升，同时研发及经营费用投入保持高位，凸显其对拓展创新管线的持续投入。以下为本年度报告的主要内容： 一、公司概况与业务重点...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180405523","title":"BAO PHARMA-B (02659): From Biotech to Foundational Operator in the 18A Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1180405523","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180405523?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:02","pubTimestamp":1776909769,"startTime":"0","endTime":"0","summary":"As Hong Kong's 18A biopharmaceutical sector approaches a period of 'value reassessment' in 2026, a profound paradigm shift centered on 'industrialized biomanufacturing' and a 'revolution in drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","02659","BK1161","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102763275","title":"BAO PHARMA-B (02659) Gains Acceptance for Recombinant Ulinastatin (BJ044) IND Application, Pioneering New Era in Recombinant Protein Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1102763275","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102763275?lang=en_us&edition=fundamental","pubTime":"2026-04-17 15:45","pubTimestamp":1776411928,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) recently announced that the Investigational New Drug (IND) application for its self-developed recombinant Ulinastatin (BJ044) has been formally accepted by the National Medical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157440551","title":"Subcutaneous Administration Breakthrough Arrives as KJ017 Gains Approval, BAO PHARMA-B (02659) Emerges as Hub for Large-Molecule Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1157440551","media":"Stock News","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157440551?lang=en_us&edition=fundamental","pubTime":"2026-04-16 13:45","pubTimestamp":1776318311,"startTime":"0","endTime":"0","summary":"After a prolonged period of valuation adjustment and structural reshaping, Hong Kong's 18A biopharmaceutical sector is reaching a critical inflection point, shifting from \"PPT-driven\" narratives to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174331901","title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1174331901","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174331901?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:58","pubTimestamp":1775714297,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135451325","title":"BAO PHARMA-B (02659) Addresses Biopharma Supply Chain Challenges with Technology-Driven Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=1135451325","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135451325?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:51","pubTimestamp":1775713881,"startTime":"0","endTime":"0","summary":"While much attention has focused on ADC and bispecific antibody pipelines with strong out-licensing potential, non-oncology pipelines have received less scrutiny. As the oncology field becomes...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625913307","title":"BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product","url":"https://stock-news.laohu8.com/highlight/detail?id=2625913307","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625913307?lang=en_us&edition=fundamental","pubTime":"2026-04-08 15:14","pubTimestamp":1775632473,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product** Shanghai Bao Pharmaceuticals 2659.HK climbs 4.4% to HK$107.3, highest since March 13** Stock set to rise for fifth straight session ** China-based pharma products researcher and developer's product, Human Hyaluronidase for Injection, with project code KJ017, approved for marketing by China's National Medical Products Administration** KJ017 is highly glycosylated recombinant human hyaluronidase used as adjuvant to subcutaneous infusion, including sodium chloride injection, sodium lactate Ringer's injection** YTD, stock up 36.8%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL1N40R07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994317","title":"Shanghai Bao Secures China Approval for Innovative Subcutaneous Delivery Adjuvant","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994317","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625994317?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:33","pubTimestamp":1775622836,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals  said Chinese regulators approved its KJ017 injection, according to a Hong Kong bourse filing Wednesday.KJ017 is an injectable version of human hyaluronidase designed to administer fluids or drugs subcutaneously, or under the skin, that the firm said is better than animal-derived hyaluronidase products.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157149079","title":"Bao Pharma’s Human Hyaluronidase Injection Receives NMPA Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1157149079","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157149079?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:21","pubTimestamp":1775622096,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) announced that its internally developed product “Human Hyaluronidase for Injection” (brand name: 葆舒宜®, project code: KJ017) in the 385U/vial dosage...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169775980","title":"BAO PHARMA-B (02659) Receives NMPA Approval for Recombinant Human Hyaluronidase Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1169775980","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169775980?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:10","pubTimestamp":1775621418,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) announced that on March 31, 2026, its self-developed, leading recombinant human hyaluronidase injection (Baoshuyi®, project code KJ017), with a specification of 385U per vial,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991606","title":"Shanghai Bao says NMPA approves human hyaluronidase injection for marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625991606?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:01","pubTimestamp":1775620893,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals won China NMPA marketing clearance for KJ017 human hyaluronidase for injection.Approval covers 385U/vial dose for use as adjuvant to subcutaneous infusion, including saline and lactated Ringer’s solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL421Bbh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991644","title":"Shanghai Bao Pharmaceuticals - Nmpa Approves Human Hyaluronidase for Injection (Kj017) for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625991644?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:00","pubTimestamp":1775620848,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q1C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164470710","title":"Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164470710","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164470710?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:45","pubTimestamp":1775119505,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital. • Capital structure...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167543547","title":"BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1167543547","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167543547?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:00","pubTimestamp":1775030424,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK4585","BK1161","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622856289","title":"BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622856289","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622856289?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:29","pubTimestamp":1774520983,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive DirectorsMarch 26  - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:PROPOSES TO ELECT LIU YANJUN, WANG ZHENG, LI CUI AS EXECUTIVE DIRECTORSFurther company coverage: 2659.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40D1AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":119,"code":"91000000","status":"200"}]}}